Category Archives: Defective Drugs

Subscribe to Defective Drugs RSS Feed

Philadelphia Risperdal Docket Almost Triples in First Half of 2017

Posted in Defective Drugs, Risperdal

The number of cases involving the anti-psychotic drug Risperdal almost tripled in the first half of 2017, jumping from approximately 2,000 cases at the beginning of the year to more than 5,500 as of June 2017, comprising the largest mass tort litigation in Philadelphia. The new filings in the Risperdal litigation were largely triggered when… Continue Reading

Third Circuit Clarifies Pleading Standard in Pay-For-Delay Suits

Posted in Defective Drugs

A Third Circuit opinion in the In re: Lipitor Antitrust Litigation reinstated the pay-for-delay lawsuit accusing pharmaceutical companies Pfizer Inc. and Ranbaxy Laboratories Inc., of delaying generic competition for Lipitor and Effexor XR. Buyers of Lipitor and Effexor XR may proceed with their antitrust claims for alleged patent fraud and anti-competitive reverse payment schemes. The appeals… Continue Reading

$417 Million Verdict in Johnson & Johnson Talcum Powder Lawsuit

Posted in Defective Drugs, Product Liability, Talcum Powder, talcum powder lawsuit

A jury has ordered Johnson & Johnson to pay $417 million to a woman who filed suit alleging that she developed ovarian cancer from using its baby powder on a regular basis for feminine hygiene. The Talcum Powder Lawsuit The lawsuit filed against Johnson & Johnson claimed that the company’s talcum powder causes ovarian cancer… Continue Reading

SCOTUS Decision in Plavix Litigation Could Lead to a Resurgence in New Jersey Mass Tort Filings

Posted in Defective Drugs, Plavix

New Jersey was once one of the premiere venues for Mass Tort filings (now termed Multicounty Litigations in New Jersey). One of the reasons for this was the obvious fact that many large pharmaceutical companies maintain their principal place of business in New Jersey, making it very difficult for those pharmaceutical companies to remove cases… Continue Reading

Ruling May Open the Door in New Jersey for Otherwise Time-Barred Cases

Posted in Accutane, Defective Drugs

The New Jersey Supreme Court recently reinstated a $25 million jury award for an Alabama man who suffered from severe inflammatory bowel disease after taking Accutane. Accutane is a prescription medication used for the treatment of acne. In June 1995, while living in Alabama, the plaintiff was prescribed Accutane by his dermatologist and took the drug… Continue Reading

Missouri Court Awards $70 Million in Johnson & Johnson Talcum Powder Lawsuit

Posted in Defective Drugs

Another talcum powder lawsuit has seen favorable results in Missouri. Unlike in New Jersey, where Multicounty Litigation (MCL) Judge Nelson C. Johnson rejected the science linking talc to ovarian cancer claims, a Missouri court again ruled in favor of the plaintiff—this time to the tune of $70 million. The plaintiff, Deborah Giannecchini of Modesto, California… Continue Reading

NJ’s Evolving Expert Opinion Standard and its Effect on Multicounty Mass Tort Litigation

Posted in Defective Drugs

On September 2, 2016, New Jersey Superior Court Judge Nelson Johnson issued an Order and Opinion barring Plaintiffs’ experts in the ongoing litigation involving claims against Johnson & Johnson, alleging ovarian cancer caused by the drug maker’s talc products. For those that follow Mass Tort litigation in New Jersey, that decision was significant, but not… Continue Reading

Xarelto Court Enters New Case Management Orders

Posted in Defective Drugs, Xarelto

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people… Continue Reading

Zofran Birth Defect Cases Consolidated in Boston, Massachusetts

Posted in Defective Drugs, Zofran

The United States Judicial Panel on Multi-District Litigation (JPML) recently assembled to determine whether the cases known as In Re: Zofran (ondansetron) Products Liability Litigation should be given Multi-District Litigation (MDL) treatment, and if so, where the litigation should be consolidated. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one… Continue Reading

The Xarelto Court’s Utilization of Pretrial Orders and Case Management Orders to Guide and Control the Multidistrict Litigation

Posted in Defective Drugs, Xarelto

Since the United States Judicial Panel on Multidistrict Litigation (“JPML”) designated the Multidistrict Litigation (“MDL”) on December 17, 2014, the United States District Court for the Eastern District of Louisiana (“EDLA”) has issued numerous Pretrial Orders and Case Management Orders to guide and control the MDL. On December 17, 2014, the EDLA issued Pretrial Order… Continue Reading

Canadian Government Launches Xarelto Investigation

Posted in Defective Drugs, Xarelto

Xarelto (rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people… Continue Reading

GlaxoSmithKline Seeks Consolidation of Zofran Lawsuits in Federal Court

Posted in Defective Drugs, Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran is commonly prescribed for use by pregnant women suffering from morning sickness. Studies show that Zofran use by pregnant women can lead to a heightened risk of… Continue Reading

Xarelto Litigation Continues to Grow

Posted in Defective Drugs, Xarelto

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Xarelto has been widely prescribed, with millions of people… Continue Reading

Zofran Litigation Continues to Grow Across the Country

Posted in Defective Drugs, Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea and vomiting…. Continue Reading

$3.6 Million Verdict in Actos Bladder Cancer Lawsuit

Posted in Actos

As we have previously reported, thousands of lawsuits have been filed against Takeda Pharmaceutical Company for its medication Actos after studies revealed that diabetics taking the drug may be at an increased risk of developing bladder cancer. In 2011, the U.S. Food and Drug Administration (FDA) warned that use of the diabetes medication Actos (pioglitazone) for more than… Continue Reading

Zofran Injuries Continue To Be Reported

Posted in Zofran

Zofran (ondansetron), manufactured by GlaxoSmithKline, is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea and vomiting. According… Continue Reading

Xarelto Cases Consolidated in New Orleans, Louisiana

Posted in Defective Drugs, Xarelto

The United States Judicial Panel on Multi-District Litigation (MDL) recently convened to determine whether the cases, known as IN RE: XARELTO (RIVAROXABAN) PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the… Continue Reading

Xarelto Injuries Continue To Be Reported

Posted in Defective Drugs, Xarelto

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Since its approval, there have been numerous reports of… Continue Reading

Xarelto Allegedly Not Safer Than Warfarin

Posted in Defective Drugs, Xarelto

Xarelto is marketed as an anticoagulant prescribed to reduce the risk of stroke, deep-vein thrombosis and pulmonary embolism. It is manufactured in the United States by Bayer and Johnson & Johnson’s New Jersey-based division, Janssen Pharmaceuticals. Lawsuits have been filed nationwide based on claims that Xarelto is responsible for injuries in some individuals. Lawsuits allege… Continue Reading